Cataract surgery in patients with neovascular age-related macular degeneration.
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Cataract surgery in patients with neovascular age-related macular degeneration. / Kessel, Line; Theil, Pernille Koefoed; Sørensen, Torben Lykke; Munch, Inger Christine.
In: Acta Ophthalmologica, Vol. 94, No. 8, 12.2016, p. 755–760 .Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Cataract surgery in patients with neovascular age-related macular degeneration.
AU - Kessel, Line
AU - Theil, Pernille Koefoed
AU - Sørensen, Torben Lykke
AU - Munch, Inger Christine
PY - 2016/12
Y1 - 2016/12
N2 - PurposeTo examine the outcome after cataract surgery in patients with neovascular age-related macular degeneration (AMD) treated with intravitreal anti-vascular endothelial growth factor (VEGF) injections in routine clinical practice.MethodsWe extracted information about patients recorded in electronic databases managing anti-VEGF injections and cataract surgery. We compared Early Treatment of Diabetic Retinopathy Study (ETDRS) visual acuity and frequency of anti-VEGF injections before and after cataract surgery.ResultsWe identified 89 eyes from 89 patients who had cataract surgery after being treated with a median of 10 (range 3–36) anti-VEGF injections for neovascular AMD. Visual acuity improved by a mean of 7.1 [95% confidence interval (CI) 4.6–9.6] ETDRS letters in the first 6 months after cataract surgery. The need of anti-VEGF injections did not change after cataract surgery with an average of 1.5 in the 6 months before surgery versus 1.7 in the 6 months after surgery (p = 0.25). Visual improvement was greater in patients when the time from latest injection to cataract surgery was lower.ConclusionsCataract surgery improves vision in patients undergoing treatment for neovascular AMD. Cataract surgery was not associated with an increased need for anti-VEGF treatment and patients who were in active anti-VEGF treatment had better visual outcomes than patients who had cataract surgery after long injection-free periods.
AB - PurposeTo examine the outcome after cataract surgery in patients with neovascular age-related macular degeneration (AMD) treated with intravitreal anti-vascular endothelial growth factor (VEGF) injections in routine clinical practice.MethodsWe extracted information about patients recorded in electronic databases managing anti-VEGF injections and cataract surgery. We compared Early Treatment of Diabetic Retinopathy Study (ETDRS) visual acuity and frequency of anti-VEGF injections before and after cataract surgery.ResultsWe identified 89 eyes from 89 patients who had cataract surgery after being treated with a median of 10 (range 3–36) anti-VEGF injections for neovascular AMD. Visual acuity improved by a mean of 7.1 [95% confidence interval (CI) 4.6–9.6] ETDRS letters in the first 6 months after cataract surgery. The need of anti-VEGF injections did not change after cataract surgery with an average of 1.5 in the 6 months before surgery versus 1.7 in the 6 months after surgery (p = 0.25). Visual improvement was greater in patients when the time from latest injection to cataract surgery was lower.ConclusionsCataract surgery improves vision in patients undergoing treatment for neovascular AMD. Cataract surgery was not associated with an increased need for anti-VEGF treatment and patients who were in active anti-VEGF treatment had better visual outcomes than patients who had cataract surgery after long injection-free periods.
U2 - 10.1111/aos.13120
DO - 10.1111/aos.13120
M3 - Journal article
C2 - 27255691
VL - 94
SP - 755
EP - 760
JO - Acta Ophthalmologica
JF - Acta Ophthalmologica
SN - 1755-375X
IS - 8
ER -
ID: 171584145